(Finance) – The stock is the protagonist on Wall Street Modern which shows an excellent performance, with an increase of 6.40%.
The news of funding of over 500 million dollars obtained by the American biotechnology company for new messenger RNA vaccines contributes to assisting the shares.
The movement of American biotechnology companyduring the week, follows the progress of the Nasdaq 100making the stock strongly influenced by the reference market and less by news relating to the company itself.
The short-term scenario of Modern highlights a decline in prices towards the USD 35.21 area with the first resistance area seen at 37.58. Expectations are for a widening of the negative phase towards the support seen at 34.19.